| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
796.44(B) |
| Last
Volume: |
1,747,701 |
Avg
Vol: |
3,278,293 |
| 52
Week Range: |
$434.7 - $815.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
505,762 |
1,375,762 |
3,014,918 |
5,975,430 |
| Total Sell Value |
$409,104,400 |
$1,016,789,780 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
10 |
22 |
49 |
89 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bertozzi Carolyn R |
Director |
– • – |
2020-11-16 |
4 |
A |
$140.59 |
$175,035 |
D/D |
1,245 |
6,243 |
|
- |
|
| Eskew Michael L |
Director |
– • – |
2020-11-16 |
4 |
A |
$140.59 |
$175,035 |
D/D |
1,245 |
43,707 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2020-11-16 |
4 |
A |
$140.59 |
$177,003 |
D/D |
1,259 |
59,651 |
|
- |
|
| Seifert Kathi P |
Director |
– • – |
2020-11-16 |
4 |
A |
$140.59 |
$175,035 |
D/D |
1,245 |
77,038 |
|
- |
|
| Walker Karen |
Director |
– • – |
2020-11-16 |
4 |
A |
$140.59 |
$175,035 |
D/D |
1,245 |
4,209 |
|
- |
|
| Baicker Katherine |
Director |
– • – |
2020-11-16 |
4 |
A |
$140.59 |
$175,035 |
D/D |
1,245 |
20,310 |
|
- |
|
| Runge Marschall S |
Director |
– • – |
2020-11-16 |
4 |
A |
$140.59 |
$175,035 |
D/D |
1,245 |
14,279 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2020-11-16 |
4 |
A |
$140.59 |
$175,035 |
D/D |
1,245 |
66,818 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2020-10-19 |
4 |
A |
$142.80 |
$1,999 |
D/D |
14 |
58,392 |
|
- |
|
| Yuffa Ilya |
SVP and Pres, Lilly Bio-MedsOf |
• – – |
2020-10-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,813 |
|
40% |
|
| Yuffa Ilya |
SVP and Pres, Lilly Bio-MedsOf |
• – – |
2020-10-04 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
6,813 |
|
- |
|
| Smiley Joshua L |
SVP and CFO |
• – – |
2020-10-01 |
4 |
D |
$148.02 |
$515,406 |
D/D |
(3,482) |
41,436 |
|
- |
|
| Smiley Joshua L |
SVP and CFO |
• – – |
2020-10-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,947 |
44,918 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2020-09-21 |
4 |
A |
$151.18 |
$1,965 |
D/D |
13 |
58,378 |
|
- |
|
| Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
• – – |
2020-09-08 |
4 |
AS |
$151.01 |
$755,050 |
D/D |
(5,000) |
23,580 |
|
35% |
|
| Mason Michael B |
Sr. VP & Pres., Lilly Diabetes |
• – – |
2020-09-01 |
4 |
D |
$148.39 |
$405,847 |
D/D |
(2,735) |
18,544 |
|
- |
|
| Mason Michael B |
Sr. VP & Pres., Lilly Diabetes |
• – – |
2020-09-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,244 |
21,279 |
|
- |
|
| Fry Stephen F |
SVP, HR & Diversity |
• – – |
2020-08-17 |
4 |
AS |
$150.64 |
$1,085,211 |
D/D |
(7,204) |
100,211 |
|
10% |
|
| Tai Jackson P |
Director |
– • – |
2020-08-17 |
4 |
A |
$151.53 |
$1,970 |
D/D |
13 |
58,301 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2020-07-20 |
4 |
A |
$167.04 |
$2,004 |
D/D |
12 |
58,288 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-07-09 |
4 |
S |
$169.68 |
$2,199,392 |
D/D |
(12,961) |
111,132,343 |
|
16% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-07-07 |
4 |
S |
$167.15 |
$35,131,799 |
D/D |
(210,000) |
111,145,304 |
|
16% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-07-06 |
4 |
S |
$166.46 |
$34,232,086 |
D/D |
(205,000) |
111,655,304 |
|
15% |
|
| Pusey Leigh Ann |
SVP, Corp. Affairs & Comm. |
• – – |
2020-07-05 |
4 |
D |
$163.87 |
$182,551 |
D/D |
(1,114) |
4,310 |
|
- |
|
| Pusey Leigh Ann |
SVP, Corp. Affairs & Comm. |
• – – |
2020-07-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,468 |
5,424 |
|
- |
|
1437 Records found
|
|
Page 22 of 58 |
|
|
1.33 (0.16%) 
